Back to top
Top
U.S. flag

An official website of the United States government

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Intravesical Bacillus-Calmette-Guerin for non-muscle invasive bladder cancer

Compare Versions of: "Intravesical Bacillus-Calmette-Guerin for non-muscle invasive bladder cancer"

The Compare function compares two years of the measure specifications found in the header of the measure's HTML. It does not include a comparison of any information in the body of the HTML, e.g., population criteria, Clinical Quality Language, or value sets.

Strikethrough text highlighted in red indicates information changed from the previous version. Text highlighted in green indicates information updated in the new eCQM version.

Compare version to

Measure Information 2022 Performance Period 2023 Performance Period 2024 Performance Period
Title Intravesical Bacillus-Calmette-Guerin for non-muscle invasive bladder cancer Intravesical Bacillus-Calmette-Guerin for non-muscle invasive bladder cancer Intravesical Bacillus-Calmette-Guerin for non-muscle invasive bladder cancer
CMS eCQM ID CMS646v2 CMS646v3 CMS646v4
NQF Number Not Applicable Not Applicable Not Applicable
Description

Percentage of patients initially diagnosed with non-muscle invasive bladder cancer and who received intravesical Bacillus-Calmette-Guerin (BCG) within 6 months of bladder cancer staging.

Percentage of patients initially diagnosed with non-muscle invasive bladder cancer and who received intravesical Bacillus-Calmette-Guerin (BCG) within 6 months of bladder cancer staging

Percentage of patients initially diagnosed with non-muscle invasive bladder cancer and who received intravesical Bacillus-Calmette-Guerin (BCG) within 6 months of bladder cancer staging

Initial Population

All patients initially diagnosed with T1, Tis or high grade Ta non-muscle invasive bladder cancer and a qualified encounter in the measurement period.

All patients initially diagnosed with T1, Tis or high grade Ta non-muscle invasive bladder cancer and a qualified encounter in the measurement period

All patients initially diagnosed with T1, Tis or high grade Ta non-muscle invasive bladder cancer with bladder cancer staging within 6 months before to 6 months after the start of the measurement period and a qualified encounter in the measurement period

Denominator

Equals Initial population

Equals Initial Population

Equals Initial Population

Denominator Exclusions Immunosuppressed patients, includes HIV and immunocompromised state.Immunosuppressive drug therapy.Active Tuberculosis.Mixed histology urothelial cell carcinoma including micropapillary, plasmacytoid, sarcomatoid, adenocarcinoma and squamous disease.Patients who undergo cystectomy, chemotherapy or radiation within 6 months of Bladder Cancer Staging. Immunosuppressed patients, includes HIV and immunocompromised state.Immunosuppressive drug therapy.Active Tuberculosis.Mixed histology urothelial cell carcinoma including micropapillary, plasmacytoid, sarcomatoid, adenocarcinoma and squamous disease.Patients who undergo cystectomy, chemotherapy or radiation within 6 months of Bladder Cancer Staging. Immunosuppressed patients, includes HIV and immunocompromised state, with a diagnosis prior to Bladder Cancer StagingImmunosuppressive drug therapy starting on or before Bladder Cancer StagingActive Tuberculosis diagnosis during the Bladder Cancer StagingMixed histology urothelial cell carcinoma including micropapillary, plasmacytoid, sarcomatoid, adenocarcinoma and squamous disease prior to Bladder Cancer StagingPatients who undergo cystectomy, chemotherapy or radiation within 6 months of Bladder Cancer Staging
Numerator

Intravesical Bacillus-Calmette Guerin (BCG) instillation for initial dose or series.

BCG is initiated within 6 months of the bladder cancer staging and during the measurement period.

Intravesical Bacillus-Calmette Guerin (BCG) instillation for initial dose or series

BCG is initiated within 6 months of the bladder cancer staging and during the measurement period

Intravesical Bacillus-Calmette Guerin (BCG) instillation for initial dose or series:

BCG is initiated within 6 months of the bladder cancer staging

Numerator Exclusions

Not Applicable

Not Applicable

Not Applicable

Denominator Exceptions

Unavailability of BCG

Unavailability of BCG

Unavailability of BCG within 6 months after Bladder Cancer Staging

Measure Steward Oregon Urology Oregon Urology Oregon Urology
Measure Scoring Proportion measure Proportion measure Proportion measure
Measure Type Process measure Process measure Process measure
Improvement Notation

A higher score is the preferred result and indicates better quality

A higher score is the preferred result and indicates better quality

A higher score is the preferred result and indicates better quality

Guidance

Ta bladder cancer must be high grade Ta only and is supported by the 2016 AUA guidelines and 2018 NCCN guidelines.

The BCG dose can be full or partial and can be from any lot or manufacturer.

This eCQM is a patient-based measure.

Telehealth encounters are not eligible for this measure because the measure requires a clinical action that cannot be conducted via telehealth.

This version of the eCQM uses QDM version 5.5. Please refer to the eCQI resource center for more information on the QDM.

Ta bladder cancer must be high grade Ta only and is supported by the 2016 AUA guidelines and 2018 NCCN guidelines.

The BCG dose can be full or partial and can be from any lot or manufacturer.

This eCQM is a patient-based measure.

Telehealth encounters are not eligible for this measure because the measure requires a clinical action that cannot be conducted via telehealth.

This version of the eCQM uses QDM version 5.6. Please refer to the QDM page for more information on the QDM.

Ta bladder cancer must be high grade Ta only and is supported by the 2016 AUA guidelines and 2018 NCCN guidelines.

The BCG dose can be full or partial and can be from any lot or manufacturer.

This eCQM is a patient-based measure.

Telehealth encounters are not eligible for this measure because the measure requires a clinical action that cannot be conducted via telehealth.

This version of the eCQM uses QDM version 5.6. Please refer to the QDM page for more information on the QDM.

MIPS Quality ID 481 481 481
Telehealth Eligible No No No
Next Version No Version Available No Version Available
Previous Version No Version Available

Header

  • Updated copyright.

    Measure Section: Copyright

    Source of Change: Annual Update

  • Updated references.

    Measure Section: Reference

    Source of Change: Measure Lead

  • Updated language in the initial population to better align with measure intent and reflect updated timing constraints.

    Measure Section: Initial Population

    Source of Change: Measure Lead

  • Updated language in the denominator exclusions to include applicable timing and align with the logic.

    Measure Section: Denominator Exclusions

    Source of Change: Measure Lead

  • Updated language in the numerator to align with the applicable timing to meet measure intent.

    Measure Section: Numerator

    Source of Change: Measure Lead

  • Updated language in the denominator exception to specify the applicable timing and align with the logic.

    Measure Section: Denominator Exceptions

    Source of Change: Measure Lead

  • Updated grammar, wording, and/or formatting to improve readability and consistency.

    Measure Section: Multiple Sections

    Source of Change: Annual Update

Logic

  • Updated the timing precision in definitions by adding 'day of' to align with the measure intent and for consistency across eCQMs.

    Measure Section: Definitions

    Source of Change: Measure Lead

  • Revised the timing of the bladder cancer staging to occur six months before or after the start of the measurement period so all data collection occurs by the end of the measurement period.

    Measure Section: Definitions

    Source of Change: Measure Lead

  • Updated the names of CQL definitions, functions, and/or aliases for clarification and to align with the CQL Style Guide.

    Measure Section: Definitions

    Source of Change: Standards/Technical Update

  • Updated definition to remove the timing constraint for the staging procedure to overlap the diagnosis for consistency with measure intent.

    Measure Section: Definitions

    Source of Change: Measure Lead

Value Set

The VSAC is the source of truth for the value set content, please visit the VSAC for downloads of current value sets.

  • Replaced value set Chemotherapy for Advanced Cancer (2.16.840.1.113883.3.7643.3.1048) with value set Chemotherapy Agents for Advanced Cancer (2.16.840.1.113762.1.4.1151.60) based on review by technical experts, SMEs, and/or public feedback.

    Measure Section: Terminology

    Source of Change: Measure Lead

  • Value set HIV (2.16.840.1.113883.3.464.1003.120.12.1003): Added 1 SNOMED CT code (1187001009) based on review by technical experts, SMEs, and/or public feedback. Deleted 3 SNOMED CT codes (72621000119104, 72631000119101, 442134007) based on review by technical experts, SMEs, and/or public feedback.

    Measure Section: Terminology

    Source of Change: Measure Lead

  • Value set Immunocompromised Conditions (2.16.840.1.113883.3.666.5.1940): Deleted 8 SNOMED CT codes (109965004, 188729005, 277473004, 277637000, 277651000, 277653002, 722953004, 190993005) based on terminology update.

    Measure Section: Terminology

    Source of Change: Annual Update

  • Value set Immunosuppressive Drugs for Urology Care (2.16.840.1.113762.1.4.1151.32): Deleted 1 RxNorm code (1551887) based on terminology update.

    Measure Section: Terminology

    Source of Change: Annual Update

  • Value set Mixed histology urothelial cell carcinoma for Urology Care (2.16.840.1.113762.1.4.1151.39): Added 1 SNOMED CT code (1187332001) based on terminology update. Deleted 1 SNOMED CT code (35917007) based on terminology update.

    Measure Section: Terminology

    Source of Change: Annual Update

  • Value set Payer (2.16.840.1.114222.4.11.3591): Added 5 SOP codes (1111, 1112, 142, 344, 141) based on review by technical experts, SMEs, and/or public feedback.

    Measure Section: Terminology

    Source of Change: Measure Lead

Last Updated: Jan 22, 2024